Stay updated with breaking news from Timothya Springer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report)’s share price reached a new 52-week low on Friday . The stock traded as low as $13.19 and last traded at $14.69, with a volume of 14103 shares changing hands. The stock had previously closed at $15.12. Wall Street Analysts Forecast Growth Separately, HC Wainwright restated a […]
/PRNewswire/ -- Sollis Health, the first concierge provider to offer its members ER-level diagnostics and care, and Prenuvo, the company pioneering proactive...
Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic’s novel GPCR-targeted therapeutic proteins $130.7 million in private financing...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
13.11.2023 - – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses ... Seite 1